Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

82.12 -2.54 (-3.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188,032
Open 85.04
Bid (Size) 81.77 (200)
Ask (Size) 82.72 (200)
Prev. Close 84.66
Today's Range 81.55 - 88.67
52wk Range 23.18 - 97.75
Shares Outstanding 11,834,361
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Bright Minds Biosciences Stock Topped the Market on Monday ↗
The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder. 
Via The Motley Fool
News headline image
Large Patient Population Is Key Driver For Bright Minds' Growth ↗
BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025 
Via Benzinga

Performance

YTD
+99.8%
+99.8%
1 Month
+25.3%
+25.3%
3 Month
+56.9%
+56.9%
6 Month
+231.4%
+231.4%
1 Year
+104.4%
+104.4%

More News

Read More
News headline image
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗
Via Benzinga
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Biotechs on the Brink: 2 Stocks With Huge Potential
Via MarketBeat
News headline image
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗
Via The Motley Fool
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
Via Benzinga
Topics Government
News headline image
What's Going On With Bright Minds Biosciences Stock? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 10/14 - 10/18
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗
Via Benzinga
News headline image
What's Going On With Bright Minds Biosciences Stock Friday? ↗
Via Benzinga
News headline image
Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗
Via Benzinga
Topics Stocks
News headline image
Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis ↗
Via Benzinga
Topics Artificial Intelligence
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
Via AB Newswire
News headline image
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views ↗
Via Benzinga
Topics Stocks
News headline image
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results ↗
Via Benzinga
News headline image
Bright Minds Biosciences Stock Surges Almost 1,500%
Via MarketBeat
News headline image
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga

Frequently Asked Questions

Is Bright Minds Biosciences Inc. - common stock publicly traded?
Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.
What exchange does Bright Minds Biosciences Inc. - common stock trade on?
Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?
The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market
What is the current price of Bright Minds Biosciences Inc. - common stock?
The current price of Bright Minds Biosciences Inc. - common stock is 82.12
When was Bright Minds Biosciences Inc. - common stock last traded?
The last trade of Bright Minds Biosciences Inc. - common stock was at 12/26/25 04:00 PM ET
What is the market capitalization of Bright Minds Biosciences Inc. - common stock?
The market capitalization of Bright Minds Biosciences Inc. - common stock is 971.84M
How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?
Bright Minds Biosciences Inc. - common stock has 972M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.